국내 만성 B형 간염 환자의 경구용 항바이러스제 사용 현황 분석
Analysis of Drug Utilization in Patients with Chronic Hepatitis B
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The treatment goal for patients with chronic hepatitis B infection is to prevent progression of the disease to cirrhosis and hepatocellular carcinoma. Current therapies include standard and pegylated interferon-alfa and nucleoside/nucleotide analogues: lamivudine, adefovir, entecavir, telbivudine, clevudine, and tenofovir. This study aims to analyze changes in theprescribing patterns of chronic hepatitis B (CHB) medications in South Korea between 2013 and 2014. Methods: A cross-sectional study was conducted using National Patients Sample data compiled by the Health Insurance Review and Assessment Service from 2013 and 2014. Patients with CHB were identified with Korean Standard Classification of Diseases code-6 (B18.0 and B18.1) and those who were maintaining active prescriptions with CHB medications covering the index date (December 1st, each year) were included. The utilization of antiviral therapy was investigated during 2013 and 2014. Results: A total of 4,204 and 4,552 patients in 2013 and 2014 respectively, were included in the analysis. The proportion of male patients was two of third and the patients 41-60 years old accounted for 60% of all analyzed patients. The most utilized drug was entecavir (55.1% in 2013 and 44.8% in 2014) and the second most utilized drug was tenofovir in both years (18.8% in 2013 and 29.0% in 2014). The percentage of combination therapy was 13.6% and 13.1% in 2013 and 2014, respectively. The proportion of tenofovir prescriptions was increased in 2014 compared with 2013. Conclusion: With the development of new drugs and the changes in clinical practice guidelines, the prescription pattern of the antiviral agents for patients with CHB has changed. The rate of utilization of tenofovir has increased.
Abstract
Background: The treatment goal for patients with chronic hepatitis B infection is to prevent progression of the disease to cirrhosis and hepatocellular carcinoma. Current therapies include standard and pegylated interferon-alfa and nucleoside/nucleotide analogues: lamivudine, adefovir, entecavir, telbivudine, clevudine, and tenofovir. This study aims to analyze changes in theprescribing patterns of chronic hepatitis B (CHB) medications in South Korea between 2013 and 2014. Methods: A cross-sectional study was conducted using National Patients Sample data compiled by the Health Insurance Review and Assessment Service from 2013 and 2014. Patients with CHB were identified with Korean Standard Classification of Diseases code-6 (B18.0 and B18.1) and those who were maintaining active prescriptions with CHB medications covering the index date (December 1st, each year) were included. The utilization of antiviral therapy was investigated during 2013 and 2014. Results: A total of 4,204 and 4,552 patients in 2013 and 2014 respectively, were included in the analysis. The proportion of male patients was two of third and the patients 41-60 years old accounted for 60% of all analyzed patients. The most utilized drug was entecavir (55.1% in 2013 and 44.8% in 2014) and the second most utilized drug was tenofovir in both years (18.8% in 2013 and 29.0% in 2014). The percentage of combination therapy was 13.6% and 13.1% in 2013 and 2014, respectively. The proportion of tenofovir prescriptions was increased in 2014 compared with 2013. Conclusion: With the development of new drugs and the changes in clinical practice guidelines, the prescription pattern of the antiviral agents for patients with CHB has changed. The rate of utilization of tenofovir has increased.
참고문헌 (26)
- "Hepatitis B. Fact Sheet No. 204"[URL]
- "Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection" (2015)[URL]
- Sarin SK, "Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update", Hepatol Int, 10(1), pp.1~98 (2016)
- Ott JJ, "Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity", Vaccine, 30(12), pp.2212~2219 (2012)
- Lozano R, "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010", Lancet, 380(9859), pp.2095~2128 (2012)
- Schweitzer A, "Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013", Lancet, 386(10003), pp.1546~1555 (2015)
- "2014 Korea Natinal Health & Nutrition Examination Survey VI 2nd"[URL]
- 이중민, "말디토프 질량 분석을 이용한 한국인의 B형간염 바이러스유전자형 및 임상적 의의에 대한 재평가", Clinical and Molecular Hepatology, 10(2004), pp.260~270 (2004), 대한간학회
- Sunbul M, "Hepatitis B virus genotypes: global distribution and clinical importance", World J Gastroenterol, 20(18), pp.5427~5434 (2014)
- Kim H, "Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea", Intervirology, 50(1), pp.52~57 (2007)
- The Korean Association for the Study of the Liver, "KASL clinical practice guidelines: management of chronic hepatitis B", Clin Mol Hepatol, 22(1), pp.18~75 (2016)
- Su MH, "Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study", World J Gastroenterol, 21(46), pp.13087~13094 (2015)
- 공혜경, "만성 B형간염 진단 환자의 항바이러스제 처방양상", 한국임상약학회지, 22(1), pp.81~86 (2012), 한국임상약학회
- Jeong JY, "Current and future of reimbursement criteria in liver disease:Reimbursement status of drugs for the treatment of hepatitis B in Asia countries and the situation and prospects in Korea", Taehan Kan Hakhoe Chi, 2012(2), pp.84~89 (2012)
- "Ministry of Health and Welfare Notification No.2013-75. Amendment of details of applicable standards and methods of reimbursement (drugs)"[URL]
- "KASL clinical practice guidelines update: management of chronic hepatitis B drug resistance"[URL]
- "Ministry of Health and Welfare Notification No.2015-68. Amendment of details of applicable standards and methods of reimbursement (drugs)"[URL]
- Kim R, "Introduction of Health Insurance Review and Assessment services'national patients sample", HIRA Policy Trends, 6, pp.37~47 (2012)
- Park SH, "Trends in the seroprevalence of hepatitis B surface antigen in the South Korean population", Int J Infect Dis, 16(9), pp.e669~e672
- Park B, "Ten-Year Changes in the Hepatitis B Prevalence in the Birth Cohorts in Korea: Results From Nationally Representative Cross-Sectional Surveys", Medicine, 94(41), pp.e1469~ (2015)
- The Korean Association for the Study of the Liver, "KASL Clinical Practice Guidelines: management of chronic hepatitis B", Clin Mol Hepatol, 18(2), pp.109~162 (2012)
- Yim HJ, "Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade", Clin Mol Hepatol, 19(3), pp.195~209 (2013)
- Wiens A, "Comparative efficacy of oral nucleoside or nucleotide analog monotherapy used in chronic hepatitis B: a mixed-treatment comparison meta-analysis", Pharmacotherapy, 33(2), pp.144~151 (2013)
- Singal AK, "Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis", Aliment Pharmacol Ther, 35(6), pp.674~689 (2012)
- Peters MG, "Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B", Gastroenterology, 126(1), pp.91~101 (2004)
- Rapti I, "Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B", Hepatology, 45(2), pp.307~313 (2007)